mshivaiah, Author at Corcept Therapeutics

About mshivaiah

This author has not written his bio yet.
But we are proud to say that mshivaiah contributed 19 entries already.

Entries by mshivaiah

Prevalence of Endogenous Hypercortisolism in Individuals With Resistant Hypertension Stratified by Kidney Function: Results From the MOMENTUM Study

DeFronzo et al. • 2026 • Heart in Diabetes

June 22, 2026

Efficacy and Safety of Relacorilant + Nab-paclitaxel in Patients Aged ≥65 Years With Platinum-resistant Ovarian Cancer (PROC) in the Phase 3 ROSELLA Study (GOG-3073, ENGOT-OV72, APGOT-Ov10)

Lorusso et al. • 2026 • ESMO Gyn

June 18, 2026

Real-World Comparative Effectiveness of Nab-paclitaxel and Standard of Care Chemotherapies in Patients With Platinum-Resistant Ovarian Cancer (COMPASS 2.0)

Shahin et al. • 2026 • ESMO Gyn

June 18, 2026

Endogenous Hypercortisolism in Individuals With Resistant Hypertension and Difficult-to-Control Type 2 Diabetes: Results From Two Large, Prospective Studies

DeFronzo et al. • 2026 • ENDO

June 15, 2026

Characterization of Individuals With Resistant Hypertension and Post-Dexamethasone Suppression Test Cortisol <1.2, 1.2–1.8, and >1.8 μg/dL: Results From the MOMENTUM Study

Eilerman et al. • 2026 • ENDO

June 15, 2026

High Prevalence of Endogenous Hypercortisolism in Patients With Type 2 Diabetes and Resistant Hypertension: Results From the MOMENTUM Study

Umpierrez et al. • 2026 • ADA

June 8, 2026

Effects of Mifepristone in People With Difficult-to-Control T2D and Hypercortisolism on GLP-1 RAs

Sloan et al. • 2026 • ADA

June 6, 2026

SYNERGY: A Phase 1b/2 Study of Nenocorilant, a Selective Glucocorticoid Receptor Antagonist, Plus Nivolumab in Patients With Advanced Solid Malignancies

Hamid et al. • 2026 • ASCO

May 30, 2026

TRIDENT: A Phase 2 Study of Relacorilant Plus Nab-paclitaxel and Gemcitabine in Chemotherapy-naïve Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Borazanci et al. • 2026 • ASCO

May 30, 2026

Overall Survival Subgroup Analyses for Prior Taxane Use in the Phase 3 ROSELLA Trial of Relacorilant Plus Nab-Paclitaxel vs Nab-Paclitaxel Monotherapy in Patients With Platinum-Resistant Ovarian Cancer

Gilbert et al. • 2026 • ASCO

May 29, 2026